Regenerative Medicine

Category

Landmark Hospitals Compassionate Use Study for Critical COVID-19 Patients Evidences Potential for Allogenic Biologic Product

Landmark Hospital manages six long-term acute care hospitals across the Southeast United States and recently announced its decision to offer an investigational allogenic biologic product derived from amniotic fluid to patients with advanced COVID-19 conditions under...

Tel Aviv Sourasky Medical Center Leases State-of-the-Art Cleanrooms to Biotechnology for Advanced Production

Tel Aviv Sourasky Medical Center has entered into an agreement to expand on an existing collaboration and lease three state-of-the-art cleanrooms with an Israeli adult stem cell therapy manufacturer, enabling the company to significantly increase their capacity to...

The FDA Approving Experimental Stem Cell Therapies Targeting Patients with Severe COVID-19 Cases

Novel medical innovations are being pursued by biotech companies and clinical investigators to halt COVID-19 causalities as there is, presently, no approved treatment for the novel coronavirus—especially in severe, escalated conditions where mortality is more...

Regenerative Research in China Targeting COVID-19 Gains Momentum—Evidence of Some Success and an American Venture

Worldwide researchers and clinical investigators develop vaccines, therapeutic treatments and diagnostic tests to take on COVID-19 and in China in addition to these activities some physicians are declaring some initial success utilizing stem cell therapy. Could this...

CSL Behring & University City Science Center Accelerate Research for New Biotherapies with Grant Awards

University of Pittsburgh and University of Delaware researchers received funding for research covering innovative therapies targeting pulmonary fibrosis (FB) to Gene delivery to or editing Hematopoietic (blood) Stem and Progenitor Cells (HSPCs). Two clinical...

Washington University Conducts Trial to Assess Breakthrough Stem Cell Production Technology

The FDA has given the green light to a first-ever clinical trial to assess the ApoGraft technology for haploidentical bone marrow transplantations to be conducted at Washington University School of Medicine in St. Louis. Sponsor is Cellect Biotechnology Ltd., (NASDAQ:...

Pin It on Pinterest